Peptides that have a Bradykinin-antagonistic effect are suitable for theproduction of drugs for use in the prophylaxis and therapy of diseases whoseprogression is associated with an increased activity of matrixmetalloproteinases. These diseases include degenerative articular diseases,for example osteoarthrosis, spondylosis and chondroporosis after joint traumaor prolonged joint immobilization after meniscus or patella injuries orruptures of a ligament.
